Hemorrhagic Fever with Renal Syndrome (HFRS): Prognosis by Severity & Treatment Timing

HFRS (caused by hantaviruses: Hantaan, Dobrava, Seoul, Puumala) progresses through febrile, hypotensive, oliguric, diuretic, convalescent phases. Prognosis depends on:

Severity-Based Outcomes

• Mild (Nephropathia epidemica - Puumala): <1% mortality; full recovery typical.
• Moderate: 1–5% mortality; recovery with possible residual renal impairment (proteinuria, ↓ GFR).
• Severe (Hantaan, Dobrava): 5–15% mortality; risks: shock, ARDS, DIC, severe AKI requiring dialysis, neurologic complications.

Critical Prognostic Factors

• Early diagnosis & supportive care: IV fluids (careful balance), electrolyte correction, renal replacement therapy (RRT) if indicated.
• Timing of RRT: Early initiation improves survival in oliguric phase.
• Comorbidities: CKD, diabetes, immunosuppression worsen outcome.
• Viral species: Hantaan/Dobrava > Seoul > Puumala severity.

Long-Term Sequelae

Most survivors recover renal function. Chronic hypertension, proteinuria, or CKD may persist in severe cases. No chronic viral persistence.

Prevention

Rodent control, avoid aerosolized excreta, PPE for high-risk occupations. Vaccines (Korea, China) for Hantaan/Seoul.